309 related articles for article (PubMed ID: 30833288)
1. In Vitro Inhibition of Carboxylesterase 1 by Major Cannabinoids and Selected Metabolites.
Qian Y; Wang X; Markowitz JS
Drug Metab Dispos; 2019 May; 47(5):465-472. PubMed ID: 30833288
[TBL] [Abstract][Full Text] [Related]
2. Cannabinoid Metabolites as Inhibitors of Major Hepatic CYP450 Enzymes, with Implications for Cannabis-Drug Interactions.
Nasrin S; Watson CJW; Perez-Paramo YX; Lazarus P
Drug Metab Dispos; 2021 Dec; 49(12):1070-1080. PubMed ID: 34493602
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of UDP-Glucuronosyltransferase Enzymes by Major Cannabinoids and Their Metabolites.
Nasrin S; Watson CJW; Bardhi K; Fort G; Chen G; Lazarus P
Drug Metab Dispos; 2021 Dec; 49(12):1081-1089. PubMed ID: 34493601
[TBL] [Abstract][Full Text] [Related]
4. The properties of UDP-glucuronyltransferase for cannabinoids in rat liver microsomes.
Watanabe K; Kita M; Yamamoto I; Oguri K; Yoshimura H
J Pharmacobiodyn; 1983 Aug; 6(8):581-7. PubMed ID: 6315914
[TBL] [Abstract][Full Text] [Related]
5. The Potential for Pharmacokinetic Interactions Between Cannabis Products and Conventional Medications.
Qian Y; Gurley BJ; Markowitz JS
J Clin Psychopharmacol; 2019; 39(5):462-471. PubMed ID: 31433338
[TBL] [Abstract][Full Text] [Related]
6. Prediction of Carboxylesterase 1-mediated In Vivo Drug Interaction between Methylphenidate and Cannabinoids using Static and Physiologically Based Pharmacokinetic Models.
Qian Y; Markowitz JS
Drug Metab Dispos; 2022 Jul; 50(7):968-979. PubMed ID: 35512806
[TBL] [Abstract][Full Text] [Related]
7. Interactions of cannabinoids with bovine serum albumin.
Haque SJ; Poddar MK
Biosci Rep; 1984 Mar; 4(3):239-43. PubMed ID: 6326885
[TBL] [Abstract][Full Text] [Related]
8. 3H-delta 9-Tetrahydrocannabinol, 3H-cannabinol and 3H-cannabidiol: penetration and regional distribution in rat brain.
Alozie SO; Martin BR; Harris LS; Dewey WL
Pharmacol Biochem Behav; 1980 Feb; 12(2):217-21. PubMed ID: 6246544
[TBL] [Abstract][Full Text] [Related]
9. Comparison in the in vitro inhibitory effects of major phytocannabinoids and polycyclic aromatic hydrocarbons contained in marijuana smoke on cytochrome P450 2C9 activity.
Yamaori S; Koeda K; Kushihara M; Hada Y; Yamamoto I; Watanabe K
Drug Metab Pharmacokinet; 2012; 27(3):294-300. PubMed ID: 22166891
[TBL] [Abstract][Full Text] [Related]
10. Kinetics of CBD, Δ
Jaidee W; Siridechakorn I; Nessopa S; Wisuitiprot V; Chaiwangrach N; Ingkaninan K; Waranuch N
Cannabis Cannabinoid Res; 2022 Aug; 7(4):537-547. PubMed ID: 34096805
[No Abstract] [Full Text] [Related]
11. Comprehensive Predictions of Cytochrome P450 (P450)-Mediated In Vivo Cannabinoid-Drug Interactions Based on Reversible and Time-Dependent P450 Inhibition in Human Liver Microsomes.
Bansal S; Paine MF; Unadkat JD
Drug Metab Dispos; 2022 Apr; 50(4):351-360. PubMed ID: 35115300
[TBL] [Abstract][Full Text] [Related]
12. Characterization of human hepatic and extrahepatic UDP-glucuronosyltransferase enzymes involved in the metabolism of classic cannabinoids.
Mazur A; Lichti CF; Prather PL; Zielinska AK; Bratton SM; Gallus-Zawada A; Finel M; Miller GP; Radomińska-Pandya A; Moran JH
Drug Metab Dispos; 2009 Jul; 37(7):1496-504. PubMed ID: 19339377
[TBL] [Abstract][Full Text] [Related]
13. Identification of glucuronides as in vivo liver conjugates of seven cannabinoids and some of their hydroxy and acid metabolites.
Harvey DJ; Martin BR; Paton WD
Res Commun Chem Pathol Pharmacol; 1977 Feb; 16(2):265-79. PubMed ID: 847285
[TBL] [Abstract][Full Text] [Related]
14. An assessment of qualitative and quantitative cannabinoids analysis in selected commercially available cannabis oils in Argentina.
Fernández N; Cappello MG; Quiroga PN
Forensic Sci Int; 2023 Aug; 349():111762. PubMed ID: 37392612
[TBL] [Abstract][Full Text] [Related]
15. Potent inhibition of human cytochrome P450 3A isoforms by cannabidiol: role of phenolic hydroxyl groups in the resorcinol moiety.
Yamaori S; Ebisawa J; Okushima Y; Yamamoto I; Watanabe K
Life Sci; 2011 Apr; 88(15-16):730-6. PubMed ID: 21356216
[TBL] [Abstract][Full Text] [Related]
16. Exogenous cannabinoids as substrates, inhibitors, and inducers of human drug metabolizing enzymes: a systematic review.
Stout SM; Cimino NM
Drug Metab Rev; 2014 Feb; 46(1):86-95. PubMed ID: 24160757
[TBL] [Abstract][Full Text] [Related]
17. Simultaneous and sensitive analysis of THC, 11-OH-THC, THC-COOH, CBD, and CBN by GC-MS in plasma after oral application of small doses of THC and cannabis extract.
Nadulski T; Sporkert F; Schnelle M; Stadelmann AM; Roser P; Schefter T; Pragst F
J Anal Toxicol; 2005; 29(8):782-9. PubMed ID: 16356335
[TBL] [Abstract][Full Text] [Related]
18. Identification of in vivo liver metabolites of delta 1-tetra-hydrocannabinol, cannabidiol, and cannabinol produced by the guninea-pig.
Harvey DJ; Martin BR; Paton WD
J Pharm Pharmacol; 1980 Apr; 32(4):267-71. PubMed ID: 6103056
[TBL] [Abstract][Full Text] [Related]
19. Predicting the Potential for Cannabinoids to Precipitate Pharmacokinetic Drug Interactions via Reversible Inhibition or Inactivation of Major Cytochromes P450.
Bansal S; Maharao N; Paine MF; Unadkat JD
Drug Metab Dispos; 2020 Oct; 48(10):1008-1017. PubMed ID: 32587099
[TBL] [Abstract][Full Text] [Related]
20. Early cannabinoid exposure influences neuroendocrine and reproductive functions in mice: II. Postnatal effects.
Dalterio S; Steger R; Mayfield D; Bartke A
Pharmacol Biochem Behav; 1984 Jan; 20(1):115-23. PubMed ID: 6320228
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
